Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.379
Eugenia Di Loreto, A. Viscardi, Cristina Maria Michela Matozzo, A. Familiari, Damiano Grippo, G. Polverino, F. Peccatori, G. Scarfone
{"title":"2022-RA-976-ESGO ALK-rearranged lung cancer and uncomplicated pregnancies on Alectinib: dream o reality?","authors":"Eugenia Di Loreto, A. Viscardi, Cristina Maria Michela Matozzo, A. Familiari, Damiano Grippo, G. Polverino, F. Peccatori, G. Scarfone","doi":"10.1136/ijgc-2022-esgo.379","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.379","url":null,"abstract":"","PeriodicalId":292924,"journal":{"name":"Fertility/Pregnancy","volume":"110 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131611818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.378
Cristina Maria Michela Matozzo, A. Viscardi, Eugenia Di Loreto, E. Grossi, V. Accurti, Beatrice De Luca Carignani, C. Castellani, G. Scarfone
2022-RA-962-ESGO Table 1 Patients’ characteristics with cancer in pregnancy Results The most common cancer was breast cancer (84.7%). Most of the cancer were diagnosed at an early stage, except for a case of IV stage lung cancer and a case of III stage ovarian cancer. Patients characteristics are shown in table 1. After multidisciplinary consultancy, patients were encouraged to continue the pregnancy and to receive a cancer treatment. Pregnancy management included standard prenatal care, ultrasound assessment of fetal growth in the third trimester and assessment of fetal wellbeing after chemotherapy administration. The mean gestational age at delivery was 36 weeks. Delivery was elective in 79% of cases, mainly due to the need to continue oncologic therapy. Mode of delivery was c-section in 56.2% and vaginal birth in 43.8%. Placental tissue was collected for histological analysis. All the babies were born alive, and only three required intensive care because of IUGR (Intrauterine Growth Restriction). No maternal, fetal or neonatal deaths were observed. Conclusion CIP is a rare but progressively increasing event. A multidisciplinary team including oncologists, obstetricians and pediatricians is crucial to balance the oncologic treatment with pregnancy management in order to avoid major neonatal complication due to iatrogenic prematurity beyond treatment’s side effects as well as safeguarding the patient therapeutic indication. 2022-RA-976-ESGO ALK-REARRANGED LUNG CANCER AND UNCOMPLICATED PREGNANCIES ON ALECTINIB: DREAM O REALITY? Eugenia Di Loreto, Anna Viscardi, Cristina Maria Michela Matozzo, Alessandra Familiari, Damiano Grippo, Gianpiero Polverino, Fedro Alessandro Peccatori, Giovanna Scarfone. Gynaecology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, Milan, Italy; Maternal-fetal medicine, Fondazione Policlinico Agostino Gemelli, Roma, Italy; Fertility and Procreation Unit, PhD, Milan, Italy 10.1136/ijgc-2022-ESGO.379 Introduction/Background Lung cancer incidence is increasing in pregnancy, partially related to advanced maternal age. A subset of patients with non-small cell lung cancer (NSCLC) harbor an Anaplastic Lymphoma Kinase (ALK) gene rerrangement. ALK-inhibitors, such as Alectinib, are promising drug to treat ALK-rearranged NSCLC, but rare safety data regarding use during pregnancy are known. Methodology We report our experience in management of two patients treated with Alectinib during pregnancy for advanced ALK rearranged lung cancer, between 2018 and 2022. Results In 2018, a 31 years old women affected of metastatic ALK-rearranged lung cancer treated with Alectinib 600 mg twice daily became pregnant by spontaneous conception. The case, occurred to our attention at 7 weeks of pregnancy, was discussed within a multidisciplinary team: the patient decided to continue pregnancy and full-dose treatment. Mother and fetus were subjected to careful clinical and instrumental investigations until delivery. We determined the
表1妊娠期癌症患者特征结果最常见的癌症为乳腺癌(84.7%)。除了1例4期肺癌和1例3期卵巢癌外，大多数癌症都在早期被诊断出来。患者特征见表1。在多学科咨询后，患者被鼓励继续怀孕并接受癌症治疗。妊娠管理包括标准的产前护理、妊娠晚期胎儿生长的超声评估和化疗后胎儿健康状况的评估。分娩时平均胎龄为36周。在79%的病例中，分娩是选择性的，主要是由于需要继续肿瘤治疗。剖宫产占56.2%，顺产占43.8%。收集胎盘组织进行组织学分析。所有婴儿出生时都是活的，只有三个婴儿因为宫内生长限制(IUGR)而需要重症监护。未观察到产妇、胎儿或新生儿死亡。结论CIP是一种少见但逐渐增加的疾病。包括肿瘤学家、产科医生和儿科医生在内的多学科团队对于平衡肿瘤治疗与妊娠管理至关重要，以避免医源性早产导致的主要新生儿并发症，而不是治疗的副作用，并保障患者的治疗指征。重新排列的肺癌和使用alec替尼的无并发症妊娠:梦想还是现实?Eugenia Di Loreto, Anna Viscardi, Cristina Maria Michela Matozzo, Alessandra Familiari, Damiano Grippo, Gianpiero Polverino, Fedro Alessandro Peccatori, Giovanna Scarfone。妇科部，意大利米兰，意大利米兰;母胎医学，意大利罗马Agostino Gemelli基金会;意大利米兰，10.1136/ijgc-2022-ESGO.379介绍/背景肺癌的发病率在妊娠期呈上升趋势，部分与高龄产妇有关。一部分非小细胞肺癌(NSCLC)患者存在间变性淋巴瘤激酶(ALK)基因重排。alk抑制剂，如Alectinib，是治疗alk重排NSCLC的有希望的药物，但很少有关于妊娠期间使用的安全性数据。我们报告了我们在2018年至2022年期间对2例妊娠期晚期ALK重排肺癌患者使用Alectinib治疗的管理经验。结果2018年，1例31岁转移性alk重排肺癌患者接受阿勒替尼600 mg每日2次治疗后自然受孕。我们在怀孕7周时注意到这个病例，在一个多学科小组中进行了讨论:患者决定继续怀孕并接受全剂量治疗。母亲和胎儿接受仔细的临床和仪器检查，直到分娩。我们测定了阿勒替尼在胎盘、羊水、母体血浆和脐带源性胎儿血浆中的水平。安全数据进一步证实了胎盘的保镖功能。到目前为止，母亲在接受肿瘤随访，婴儿在接受儿科随访。我们目前正在跟踪另一名38岁的患者，他受到相同病理和治疗的影响。她是在接受治疗的情况下自然受孕的，现在已经怀孕31周了:到目前为止，对妈妈和胎儿都没有副作用。结论这些病例，虽然只有两个，揭示了妊娠期间阿勒替尼并不一定与胚胎发育的可检测变化有关。目前，接受这种新药治疗的有生育能力的患者必须建议采取避孕措施，但如果想要成为母亲或正在怀孕，一个多学科的团队应该安慰患者做出选择:一个知情的患者可以有意识地做出选择。保留生育能力会影响乳腺癌肿瘤治疗的开始和对新辅助化疗的反应吗?Sonia Baulies, Marta Devesa, Francesc Tresserra, Maxim Izquierdo, Francesc Fargas, Ignacio Rodríguez, Rafael Fàbregas。妇科肿瘤及乳腺病理科。意大利大学医院妇产科生殖科Quirón-Dexeus。巴塞罗那，西班牙，巴塞罗那，西班牙;医院大学Quirón-Dexeus。巴塞罗那,西班牙
{"title":"2022-RA-962-ESGO Cancer in pregnancy: message in a bottle from tertiary center of Milan","authors":"Cristina Maria Michela Matozzo, A. Viscardi, Eugenia Di Loreto, E. Grossi, V. Accurti, Beatrice De Luca Carignani, C. Castellani, G. Scarfone","doi":"10.1136/ijgc-2022-esgo.378","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.378","url":null,"abstract":"2022-RA-962-ESGO Table 1 Patients’ characteristics with cancer in pregnancy Results The most common cancer was breast cancer (84.7%). Most of the cancer were diagnosed at an early stage, except for a case of IV stage lung cancer and a case of III stage ovarian cancer. Patients characteristics are shown in table 1. After multidisciplinary consultancy, patients were encouraged to continue the pregnancy and to receive a cancer treatment. Pregnancy management included standard prenatal care, ultrasound assessment of fetal growth in the third trimester and assessment of fetal wellbeing after chemotherapy administration. The mean gestational age at delivery was 36 weeks. Delivery was elective in 79% of cases, mainly due to the need to continue oncologic therapy. Mode of delivery was c-section in 56.2% and vaginal birth in 43.8%. Placental tissue was collected for histological analysis. All the babies were born alive, and only three required intensive care because of IUGR (Intrauterine Growth Restriction). No maternal, fetal or neonatal deaths were observed. Conclusion CIP is a rare but progressively increasing event. A multidisciplinary team including oncologists, obstetricians and pediatricians is crucial to balance the oncologic treatment with pregnancy management in order to avoid major neonatal complication due to iatrogenic prematurity beyond treatment’s side effects as well as safeguarding the patient therapeutic indication. 2022-RA-976-ESGO ALK-REARRANGED LUNG CANCER AND UNCOMPLICATED PREGNANCIES ON ALECTINIB: DREAM O REALITY? Eugenia Di Loreto, Anna Viscardi, Cristina Maria Michela Matozzo, Alessandra Familiari, Damiano Grippo, Gianpiero Polverino, Fedro Alessandro Peccatori, Giovanna Scarfone. Gynaecology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, Milan, Italy; Maternal-fetal medicine, Fondazione Policlinico Agostino Gemelli, Roma, Italy; Fertility and Procreation Unit, PhD, Milan, Italy 10.1136/ijgc-2022-ESGO.379 Introduction/Background Lung cancer incidence is increasing in pregnancy, partially related to advanced maternal age. A subset of patients with non-small cell lung cancer (NSCLC) harbor an Anaplastic Lymphoma Kinase (ALK) gene rerrangement. ALK-inhibitors, such as Alectinib, are promising drug to treat ALK-rearranged NSCLC, but rare safety data regarding use during pregnancy are known. Methodology We report our experience in management of two patients treated with Alectinib during pregnancy for advanced ALK rearranged lung cancer, between 2018 and 2022. Results In 2018, a 31 years old women affected of metastatic ALK-rearranged lung cancer treated with Alectinib 600 mg twice daily became pregnant by spontaneous conception. The case, occurred to our attention at 7 weeks of pregnancy, was discussed within a multidisciplinary team: the patient decided to continue pregnancy and full-dose treatment. Mother and fetus were subjected to careful clinical and instrumental investigations until delivery. We determined the","PeriodicalId":292924,"journal":{"name":"Fertility/Pregnancy","volume":"96 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132583174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.386
A. Bergamini, F. Vasta, L. Bocciolone, G. Scarfone, C. Cassani, G. Ferrandina, R. de Vivo, S. Danese, M. Filippo, Elisa Grassi, G. Cormio, S. Pignata, G. Mangili
{"title":"2022-RA-1433-ESGO Reproductive outcomes after conservative treatment in malignant ovarian germ cell tumors (MOGCTs) patients: a MITO-9 study","authors":"A. Bergamini, F. Vasta, L. Bocciolone, G. Scarfone, C. Cassani, G. Ferrandina, R. de Vivo, S. Danese, M. Filippo, Elisa Grassi, G. Cormio, S. Pignata, G. Mangili","doi":"10.1136/ijgc-2022-esgo.386","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.386","url":null,"abstract":"","PeriodicalId":292924,"journal":{"name":"Fertility/Pregnancy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133365851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.377
G. Marino, T. Grassi, Filippo Testa, Serena Negri, E. De Ponti, D. Giuliani, M. D. Marchette, F. Sina, Diletta Fumagalli, D. Vicini, Mariaclara Boccadutri, Maria Cristina Bonazzi, F. Landoni, R. Fruscio
{"title":"2022-RA-870-ESGO Fertility outcome of patients with stage I immature teratoma – do surgical approach and post-surgical treatment matter?","authors":"G. Marino, T. Grassi, Filippo Testa, Serena Negri, E. De Ponti, D. Giuliani, M. D. Marchette, F. Sina, Diletta Fumagalli, D. Vicini, Mariaclara Boccadutri, Maria Cristina Bonazzi, F. Landoni, R. Fruscio","doi":"10.1136/ijgc-2022-esgo.377","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.377","url":null,"abstract":"","PeriodicalId":292924,"journal":{"name":"Fertility/Pregnancy","volume":"81 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123343408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：